SpectraCure — Investor Relations & Filings

SpectraCure is a medical technology company developing a minimally invasive, next-generation treatment system for internal solid tumors. The company's primary focus is on providing a highly precise, focal therapy for localized prostate cancer, targeting both primary tumors and recurrent cancer after previous radiation therapy. The system is designed to destroy cancer cells with high precision while minimizing damage to surrounding healthy tissue. Clinical trials for the treatment are underway at leading cancer clinics in North America and Europe. The technology platform has the potential to be adapted for other solid tumors, including those in the breast, pancreas, and the head and neck region, aiming to offer a more individualized and effective treatment solution.